2025 Q4 -tulosraportti
Vain PDF
30 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenLAST WORDS BEFORE BOSTON: REALITY CHECK AND THE LONG GAME ⏳🧬 It's getting crowded at the door now, and you can feel the pressure. But let's take a breather before it all kicks off tomorrow: Even if we are served elite data on the main stage, this is still a long-term race. Biotech is not a sprint. For those looking for the truly big values – the massive partnerships and the clinical breakthroughs – the real case, in my view, lies in late 2026 and early 2027. Why? Because system validation and regulatory processes are complex matters. Things take time. At the same time, we know that in this game, things can happen much faster than one might expect when the right eyes first see the source code and understand the architecture – but I am building my thesis on the fundamental race. I'm wrapping up here and taking a break from the keyboard until the real news and numbers are actually on the table. Tomorrow will be a good day for everyone who has done their homework. We have the data, we have the stage, and we have the foundation. We'll talk when the facts are available. 🚀 We know what we own. ♟️🧱🍷
·37 min sittenHi Bennyz I myself am operating with half a million out here, can afford to lose this money., But don't Lu edd others out into this madness, Win or disappear. I have been on Vadino before, to put it that way. Hope of course we all here we all succeed. Good weekend to you all. Money rules 🙏🥃😆
5 t sitten5 t sittenVideo at ASGCT with Erik Wiklund: https://www.biotechtv.com/post/asgct-2026-circio Very interesting to say the least. Erik Wiklund describes the advantages of circular RNA, and points out the great work in heart and eye, and also mentions in vivo CAR-T. Just want to highlight the competition when it comes to in vivo CAR-T at the ASGCT conference for those not in Boston, or reading all the abstracts: there was a late breaking abstract from the Nobel laureate, and serial company start-up entrepreneur jennifer Doudna, co-founder of Azalea Therapeutics, that got a lot of attention, demonstrating first-in-primate in vivo TRAC-CAR T cell enginering: today’s CAR-T therapies are highly effective at treating certain cancers, but patients’ cells have to be removed, reengineered in a facility, and then reinfused into the patient - a toxic, very expensive, and cumbersome process. Investors and pharma companies are spending billions to create alternatives that transform patients’ cells in their body - in vivo CAR- T reprogramming. Jennifer Doudna’s spinoff aims to turn patients’ immune cells into CAR-T fighters with single shot. Here is a Nature publication describing the tech: https://www.nature.com/articles/s41586-026-10235-x Azalea’s primary advantage is therapeutic permanence; because the CAR gene is integrated directly into the host genome, the modified T cells maintain long-lasting, curative tumor-hunting capabilities even as they divide rapidly inside the patient. However, it faces a tight payload capacity bottleneck dictated by the strict packaging limits of its helper AAV vector. The down side (or upsie, depending on how you view it) is the need for permanent genetic changes, and capacity of payload. Circio's platform offers a massive cargo capacity advantage, enabling the expression of larger, multi-targeted genetic structures without viral sizing constraints. Azalea focuses entirely on permanent genomic reprogramming. Its CRISPR scissors execute a precise cut at the native T Cell Receptor Alpha Constant (TRAC) locus, seamlessly inserting the CAR payload so that the body's internal cellular promoters natively regulate expression. Circio’s circVec platform avoids genomic editing entirely, relying on temporary epigenetic expression. Its cassettes loop the transcribed therapeutic message into a seamless, circular RNA (circRNA) structure that sits inside the cell without permanently splitting or mutating the host's native DNA. So, pros and cons with both metods. But Azalea is a few steps ahead, and already have first-in-primate data, presented at ASGCT: https://distribution.us.m-anage.com/from.storage?image=Kn0KAtCjscVNEYTvg0_NV1eWFlxOzq9ak6GkWgEi2jEoPoLnBPt1MJyl5cjy9Qr60 Exciting times indeed! Support research and betterment of patient outcomes by buying stock ;)
·5 t sittenOn Monday this can actually stand at 25 kr- ·5 t sittenFRIDAY IS NOT THE END OF BOSTON. IT IS THE START OF THE CLOSED ROOMS. 🧬🚪💰 Many believe that when the ASGCT curtain goes down tomorrow, the show is over. They are brutally wrong. The conference is just a showcase. The backroom meeting rooms are where the price tag is set. And after Wiklund's latest interview, one thing is crystal clear: Circio does not enter those meeting rooms with cap in hand. They enter with power. Here is the industrial logic people overlook before the weekend: 1. CAPITAL = NEGOTIATING POWER 🛣️💸 Wiklund said it straight out: The financing is secured. Through the VWAP mechanism and the existing runway, the company has secured the most important thing in biotech: Time. In biotech, a company without money is prey. A company with money is a partner. Circio no longer needs to accept the first and best "crumb-deal" to survive. They can afford to run several parallel in vivo studies on their own. Eye. Heart. CNS. Simultaneously. Each self-financed data package drives up the price of the technology. 2. THE PANIC AT BIG PHARMA 🏎️🚨 People think big licensing agreements and upfront payments always take years. Wrong. Things take time until someone panics. When you show the world elite: • 40x expression in heart. • 22x dose reduction. • And that a Top-5 Pharma giant is already testing the technology on CNS... Then competitors start to sweat. Licensing agreements happen when a giant realizes they cannot afford for the neighbor to get the technology first. With the data now open in Boston, the "best case" can hit the market much faster than anyone dares to price in. 3. THE LAST WINDOW BEFORE THE WEEKEND ⏳ Tomorrow evening they go on stage (Oral Presentation). After that, "our secret" is common knowledge among the global gene therapy elite. Friday is the last trading day this week. When retail investors take the weekend off, Business Development directors from Big Pharma get on their planes home. They are not going to relax. They are going to calculate what circVec can do for their own freezing pipelines. The market stares at Friday's closing price. Wiklund is preparing for industrial scaling. You can try to trade a few cents back and forth tomorrow. Or you can understand that the company just went from defensive survival to offensive dominance. The source code is delivered. The machinery is running. We know what we own. ♟️🧱🍷
·5 t sittenIf one hears something often enough, it can become a truth. I must say I think there's a lot of nonsense in here at times. But people who speak loudly should show their cards for their own credibility. Then it also becomes more interesting to read what people write. In many cases, those who shout the loudest show nothing. That's a bit of a shame. Because I honestly believe the quality in the forum would have improved. Yes, I know it's 100 percent voluntary.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
30 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenLAST WORDS BEFORE BOSTON: REALITY CHECK AND THE LONG GAME ⏳🧬 It's getting crowded at the door now, and you can feel the pressure. But let's take a breather before it all kicks off tomorrow: Even if we are served elite data on the main stage, this is still a long-term race. Biotech is not a sprint. For those looking for the truly big values – the massive partnerships and the clinical breakthroughs – the real case, in my view, lies in late 2026 and early 2027. Why? Because system validation and regulatory processes are complex matters. Things take time. At the same time, we know that in this game, things can happen much faster than one might expect when the right eyes first see the source code and understand the architecture – but I am building my thesis on the fundamental race. I'm wrapping up here and taking a break from the keyboard until the real news and numbers are actually on the table. Tomorrow will be a good day for everyone who has done their homework. We have the data, we have the stage, and we have the foundation. We'll talk when the facts are available. 🚀 We know what we own. ♟️🧱🍷·37 min sittenHi Bennyz I myself am operating with half a million out here, can afford to lose this money., But don't Lu edd others out into this madness, Win or disappear. I have been on Vadino before, to put it that way. Hope of course we all here we all succeed. Good weekend to you all. Money rules 🙏🥃😆
- 5 t sitten5 t sittenVideo at ASGCT with Erik Wiklund: https://www.biotechtv.com/post/asgct-2026-circio Very interesting to say the least. Erik Wiklund describes the advantages of circular RNA, and points out the great work in heart and eye, and also mentions in vivo CAR-T. Just want to highlight the competition when it comes to in vivo CAR-T at the ASGCT conference for those not in Boston, or reading all the abstracts: there was a late breaking abstract from the Nobel laureate, and serial company start-up entrepreneur jennifer Doudna, co-founder of Azalea Therapeutics, that got a lot of attention, demonstrating first-in-primate in vivo TRAC-CAR T cell enginering: today’s CAR-T therapies are highly effective at treating certain cancers, but patients’ cells have to be removed, reengineered in a facility, and then reinfused into the patient - a toxic, very expensive, and cumbersome process. Investors and pharma companies are spending billions to create alternatives that transform patients’ cells in their body - in vivo CAR- T reprogramming. Jennifer Doudna’s spinoff aims to turn patients’ immune cells into CAR-T fighters with single shot. Here is a Nature publication describing the tech: https://www.nature.com/articles/s41586-026-10235-x Azalea’s primary advantage is therapeutic permanence; because the CAR gene is integrated directly into the host genome, the modified T cells maintain long-lasting, curative tumor-hunting capabilities even as they divide rapidly inside the patient. However, it faces a tight payload capacity bottleneck dictated by the strict packaging limits of its helper AAV vector. The down side (or upsie, depending on how you view it) is the need for permanent genetic changes, and capacity of payload. Circio's platform offers a massive cargo capacity advantage, enabling the expression of larger, multi-targeted genetic structures without viral sizing constraints. Azalea focuses entirely on permanent genomic reprogramming. Its CRISPR scissors execute a precise cut at the native T Cell Receptor Alpha Constant (TRAC) locus, seamlessly inserting the CAR payload so that the body's internal cellular promoters natively regulate expression. Circio’s circVec platform avoids genomic editing entirely, relying on temporary epigenetic expression. Its cassettes loop the transcribed therapeutic message into a seamless, circular RNA (circRNA) structure that sits inside the cell without permanently splitting or mutating the host's native DNA. So, pros and cons with both metods. But Azalea is a few steps ahead, and already have first-in-primate data, presented at ASGCT: https://distribution.us.m-anage.com/from.storage?image=Kn0KAtCjscVNEYTvg0_NV1eWFlxOzq9ak6GkWgEi2jEoPoLnBPt1MJyl5cjy9Qr60 Exciting times indeed! Support research and betterment of patient outcomes by buying stock ;)
- ·5 t sittenOn Monday this can actually stand at 25 kr
- ·5 t sittenFRIDAY IS NOT THE END OF BOSTON. IT IS THE START OF THE CLOSED ROOMS. 🧬🚪💰 Many believe that when the ASGCT curtain goes down tomorrow, the show is over. They are brutally wrong. The conference is just a showcase. The backroom meeting rooms are where the price tag is set. And after Wiklund's latest interview, one thing is crystal clear: Circio does not enter those meeting rooms with cap in hand. They enter with power. Here is the industrial logic people overlook before the weekend: 1. CAPITAL = NEGOTIATING POWER 🛣️💸 Wiklund said it straight out: The financing is secured. Through the VWAP mechanism and the existing runway, the company has secured the most important thing in biotech: Time. In biotech, a company without money is prey. A company with money is a partner. Circio no longer needs to accept the first and best "crumb-deal" to survive. They can afford to run several parallel in vivo studies on their own. Eye. Heart. CNS. Simultaneously. Each self-financed data package drives up the price of the technology. 2. THE PANIC AT BIG PHARMA 🏎️🚨 People think big licensing agreements and upfront payments always take years. Wrong. Things take time until someone panics. When you show the world elite: • 40x expression in heart. • 22x dose reduction. • And that a Top-5 Pharma giant is already testing the technology on CNS... Then competitors start to sweat. Licensing agreements happen when a giant realizes they cannot afford for the neighbor to get the technology first. With the data now open in Boston, the "best case" can hit the market much faster than anyone dares to price in. 3. THE LAST WINDOW BEFORE THE WEEKEND ⏳ Tomorrow evening they go on stage (Oral Presentation). After that, "our secret" is common knowledge among the global gene therapy elite. Friday is the last trading day this week. When retail investors take the weekend off, Business Development directors from Big Pharma get on their planes home. They are not going to relax. They are going to calculate what circVec can do for their own freezing pipelines. The market stares at Friday's closing price. Wiklund is preparing for industrial scaling. You can try to trade a few cents back and forth tomorrow. Or you can understand that the company just went from defensive survival to offensive dominance. The source code is delivered. The machinery is running. We know what we own. ♟️🧱🍷
- ·5 t sittenIf one hears something often enough, it can become a truth. I must say I think there's a lot of nonsense in here at times. But people who speak loudly should show their cards for their own credibility. Then it also becomes more interesting to read what people write. In many cases, those who shout the loudest show nothing. That's a bit of a shame. Because I honestly believe the quality in the forum would have improved. Yes, I know it's 100 percent voluntary.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
30 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenLAST WORDS BEFORE BOSTON: REALITY CHECK AND THE LONG GAME ⏳🧬 It's getting crowded at the door now, and you can feel the pressure. But let's take a breather before it all kicks off tomorrow: Even if we are served elite data on the main stage, this is still a long-term race. Biotech is not a sprint. For those looking for the truly big values – the massive partnerships and the clinical breakthroughs – the real case, in my view, lies in late 2026 and early 2027. Why? Because system validation and regulatory processes are complex matters. Things take time. At the same time, we know that in this game, things can happen much faster than one might expect when the right eyes first see the source code and understand the architecture – but I am building my thesis on the fundamental race. I'm wrapping up here and taking a break from the keyboard until the real news and numbers are actually on the table. Tomorrow will be a good day for everyone who has done their homework. We have the data, we have the stage, and we have the foundation. We'll talk when the facts are available. 🚀 We know what we own. ♟️🧱🍷·37 min sittenHi Bennyz I myself am operating with half a million out here, can afford to lose this money., But don't Lu edd others out into this madness, Win or disappear. I have been on Vadino before, to put it that way. Hope of course we all here we all succeed. Good weekend to you all. Money rules 🙏🥃😆
- 5 t sitten5 t sittenVideo at ASGCT with Erik Wiklund: https://www.biotechtv.com/post/asgct-2026-circio Very interesting to say the least. Erik Wiklund describes the advantages of circular RNA, and points out the great work in heart and eye, and also mentions in vivo CAR-T. Just want to highlight the competition when it comes to in vivo CAR-T at the ASGCT conference for those not in Boston, or reading all the abstracts: there was a late breaking abstract from the Nobel laureate, and serial company start-up entrepreneur jennifer Doudna, co-founder of Azalea Therapeutics, that got a lot of attention, demonstrating first-in-primate in vivo TRAC-CAR T cell enginering: today’s CAR-T therapies are highly effective at treating certain cancers, but patients’ cells have to be removed, reengineered in a facility, and then reinfused into the patient - a toxic, very expensive, and cumbersome process. Investors and pharma companies are spending billions to create alternatives that transform patients’ cells in their body - in vivo CAR- T reprogramming. Jennifer Doudna’s spinoff aims to turn patients’ immune cells into CAR-T fighters with single shot. Here is a Nature publication describing the tech: https://www.nature.com/articles/s41586-026-10235-x Azalea’s primary advantage is therapeutic permanence; because the CAR gene is integrated directly into the host genome, the modified T cells maintain long-lasting, curative tumor-hunting capabilities even as they divide rapidly inside the patient. However, it faces a tight payload capacity bottleneck dictated by the strict packaging limits of its helper AAV vector. The down side (or upsie, depending on how you view it) is the need for permanent genetic changes, and capacity of payload. Circio's platform offers a massive cargo capacity advantage, enabling the expression of larger, multi-targeted genetic structures without viral sizing constraints. Azalea focuses entirely on permanent genomic reprogramming. Its CRISPR scissors execute a precise cut at the native T Cell Receptor Alpha Constant (TRAC) locus, seamlessly inserting the CAR payload so that the body's internal cellular promoters natively regulate expression. Circio’s circVec platform avoids genomic editing entirely, relying on temporary epigenetic expression. Its cassettes loop the transcribed therapeutic message into a seamless, circular RNA (circRNA) structure that sits inside the cell without permanently splitting or mutating the host's native DNA. So, pros and cons with both metods. But Azalea is a few steps ahead, and already have first-in-primate data, presented at ASGCT: https://distribution.us.m-anage.com/from.storage?image=Kn0KAtCjscVNEYTvg0_NV1eWFlxOzq9ak6GkWgEi2jEoPoLnBPt1MJyl5cjy9Qr60 Exciting times indeed! Support research and betterment of patient outcomes by buying stock ;)
- ·5 t sittenOn Monday this can actually stand at 25 kr
- ·5 t sittenFRIDAY IS NOT THE END OF BOSTON. IT IS THE START OF THE CLOSED ROOMS. 🧬🚪💰 Many believe that when the ASGCT curtain goes down tomorrow, the show is over. They are brutally wrong. The conference is just a showcase. The backroom meeting rooms are where the price tag is set. And after Wiklund's latest interview, one thing is crystal clear: Circio does not enter those meeting rooms with cap in hand. They enter with power. Here is the industrial logic people overlook before the weekend: 1. CAPITAL = NEGOTIATING POWER 🛣️💸 Wiklund said it straight out: The financing is secured. Through the VWAP mechanism and the existing runway, the company has secured the most important thing in biotech: Time. In biotech, a company without money is prey. A company with money is a partner. Circio no longer needs to accept the first and best "crumb-deal" to survive. They can afford to run several parallel in vivo studies on their own. Eye. Heart. CNS. Simultaneously. Each self-financed data package drives up the price of the technology. 2. THE PANIC AT BIG PHARMA 🏎️🚨 People think big licensing agreements and upfront payments always take years. Wrong. Things take time until someone panics. When you show the world elite: • 40x expression in heart. • 22x dose reduction. • And that a Top-5 Pharma giant is already testing the technology on CNS... Then competitors start to sweat. Licensing agreements happen when a giant realizes they cannot afford for the neighbor to get the technology first. With the data now open in Boston, the "best case" can hit the market much faster than anyone dares to price in. 3. THE LAST WINDOW BEFORE THE WEEKEND ⏳ Tomorrow evening they go on stage (Oral Presentation). After that, "our secret" is common knowledge among the global gene therapy elite. Friday is the last trading day this week. When retail investors take the weekend off, Business Development directors from Big Pharma get on their planes home. They are not going to relax. They are going to calculate what circVec can do for their own freezing pipelines. The market stares at Friday's closing price. Wiklund is preparing for industrial scaling. You can try to trade a few cents back and forth tomorrow. Or you can understand that the company just went from defensive survival to offensive dominance. The source code is delivered. The machinery is running. We know what we own. ♟️🧱🍷
- ·5 t sittenIf one hears something often enough, it can become a truth. I must say I think there's a lot of nonsense in here at times. But people who speak loudly should show their cards for their own credibility. Then it also becomes more interesting to read what people write. In many cases, those who shout the loudest show nothing. That's a bit of a shame. Because I honestly believe the quality in the forum would have improved. Yes, I know it's 100 percent voluntary.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt